Bioxytran (BIXT) Prepaid Assets (2011 - 2025)
Bioxytran (BIXT) posted Prepaid Assets of $3551.0 for Q4 2025, down 99.29% sequentially from $499300.0 in Q3 2021.
Bioxytran (BIXT) Prepaid Assets (2011 - 2025) Analysis & Trends
Bioxytran has reported Prepaid Assets for 6 years, with the latest figure at $3551.0 in Q4 2025.
- Quarterly Prepaid Assets changed N/A year-over-year to $3551.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3551.0 (changed N/A YoY) and the FY2025 annual result came in at $3551.0, changed N/A from the prior year.
- Prepaid Assets slipped to $3551.0 in Q4 2025 per BIXT's latest filing, from $499300.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $499300.0 in Q2 2021 and troughed at $3551.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - |
| 10 | Bioxytran | 2.29 Mn | 2.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,551.00 |
| Sep 30, 2021 | 499,300.00 |
| Jun 30, 2021 | 499,300.00 |
| Mar 31, 2021 | 274,715.00 |
| Dec 31, 2020 | 274,715.00 |
| Dec 31, 2019 | 50,000.00 |
| Dec 31, 2012 | 254,600.00 |
| Jun 30, 2012 | 1,500.00 |
| Mar 31, 2012 | 3,750.00 |
| Dec 31, 2011 | 6,500.00 |
| Sep 30, 2011 | 8,249.00 |